HUTCHMED (HCM) Share Price, News & Analysis

Company Overview

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).

Key Stats

• Today's Range: 232 to 240
• 50-Day Range: 211 to 268
• 52-Week Range: 206 to 353
• Volume: 57,578 shs
• Average Volume: 45,727 shs
• Market Capitalization: £2.57 billion
• P/E Ratio: N/A
• Dividend Yield: 4.63%
• Price Target: N/A
• Consensus Rating: N/A

HCM Stock Analysis - Frequently Asked Questions

How have HCM shares performed this year?

HUTCHMED's stock was trading at GBX 235 at the beginning of the year. Since then, HCM stock has increased by 0.9% and is now trading at GBX 237.
View the best growth stocks for 2025 here.

How do I buy shares of HUTCHMED?

Shares of HCM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include Intelsat (I), Associated British Foods (ABF), Chaarat Gold (CGH), Bank of America (BAC), Fossil Group (FOSL), AMC Entertainment (AMC) and Air Canada (AC).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:HCM
• CIK: N/A
• Web: www.chi-med.com
• Phone: +85221213888
• Fax: N/A
• Employees: 1,760
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (3.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 48.89
• P/E Growth: N/A
• Net Income: £-52,977,884.40
• Net Margins: -6.87%
• Pretax Margin: N/A
• Return on Equity: -5.71%
• Return on Assets: -5.90%

Debt

• Debt-to-Equity Ratio: 11.97
• Current Ratio: 2.81
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: £771.01 million
• Price / Sales: 3.34
• Cash Flow: GBX 94.99 per share
• Price / Cash Flow: 2.49
• Book Value: GBX 87.44 per share
• Price / Book: 2.71

Miscellaneous

• Outstanding Shares: 1,085,602,728
• Free Float: N/A
• Market Cap: £2.57 billion
• Optionable: Not Optionable
• Beta: 0.76